Tag: TAVR

BayCare Receives Recognition for its Minimally Invasive Transcatheter Valve Procedures

CLEARWATER, Fla., June 23, 2022 /PRNewswire/ — The structural heart programs at BayCare’s Morton Plant Hospital in Clearwater and St. Joseph’s Hospital in Tampa recently received the American College of Cardiology (ACC) Transcatheter Valve Certification. The certification recognizes each program’s expertise and commitment to excellence in […]

VenusP-Valve(TM) obtains CE marking under MDR and debuts in Europe as China’s first valve product

HANGZHOU, China, April 11, 2022 /PRNewswire/ — On April 8th, 2022, VenusP-ValveTM, Venus Medtech’s in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, received CE marking under the Medical Devices Regulation (MDR) to be marketed in Europe. Designed to treat patients with moderate to […]

Venus Medtech announces 2021 annual results: pacesetter in China and breakthrough-maker worldwide

HANGZHOU, China, March 31, 2022 /PRNewswire/ — On March 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as “Venus Medtech”), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its annual results for the year ended December […]

Vizient Medical Device Tech Watch Provides Trends in Transcatheter Valve Replacement and a Model for Assessing New Technology in Musculoskeletal Care

IRVING, Texas–(BUSINESS WIRE)–In its latest Medical Device Tech Watch, Vizient, Inc. provides updated trends in patient quality outcomes for transcatheter valve replacement, including insights for complications and physician expertise. In addition, this issue presents a technology adoption model for assessing the clinical […]

Eisenhower Health First in California to Complete Edwards Benchmark™ Program for Transcatheter Aortic Valve Replacement (TAVR)

ONLY HOSPITAL IN COACHELLA VALLEY TO OFFER TAVR RANCHO MIRAGE, Calif., Dec. 16, 2021 /PRNewswire/ — Eisenhower Health is the FIRST hospital in California to be recognized by Edwards Lifesciences for completing its Edwards Benchmark program for the treatment of aortic stenosis in patients undergoing […]

TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis

IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost. This […]